Question follow-through · 33376

Fenfluramine

To ask the Secretary of State for Health and Social Care, what discussions he has had with the National Institute for Health and Care Excellence on the use of Fenfluramine to treat Lennox Gastaut Syndrome; and what representations his Department has had f

answeredDepartment of Health and Social Care

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department of Health and Social Care
Tabled
25 Feb 2025
Target answer date
3 Mar 2025
Answer
3 Mar 2025 · 6 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

More questions by this MP on Health and care

Shared topic keywords suggest a connection; they do not establish a follow-up.

Votes on this topic

These Commons divisions share a topic label. The question did not necessarily lead to a vote.

Recorded timeline

  1. 25 Feb 2025

    Question tabled

    To ask the Secretary of State for Health and Social Care, what discussions he has had with the National Institute for Health and Care Excellence on the use of Fenfluramine to treat Lennox Gastaut Syndrome; and what representations his Department has had f

  2. 3 Mar 2025

    Target answer date

    Date supplied by the official written-questions record.

  3. 3 Mar 2025

    Answer published

    The National Institute for Health and Care Excellence (NICE) develops its guidance on new medicines independently and the Department has had no discussions with the NICE about its appraisal of fenfluramine for the treatment of Lennox Gastaut syndrome. Fur...

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Surgical Mesh Implants

26 Feb 2025 · To ask the Secretary of State for Health and Social Care, if he will take steps to commission (a) research into, and (b) training programmes for, improved techniques for removal of failed pelvic mesh implants from injured women including those removal met

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Surgical Mesh Implants: Compensation

26 Feb 2025 · To ask the Secretary of State for Health and Social Care, how many legal cases brought against the NHS by mesh-damaged women have been settled (a) in and (b) out of court in each of the past ten years.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Surgical Mesh Implants

26 Feb 2025 · To ask the Secretary of State for Health and Social Care, if he will publish current waiting lists totals at each of the mesh removal centres set up following the publication of the Cumberlege report; and whether mesh-damaged women are given an option to

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Palliative Care: Children

31 Mar 2025 · To ask the Secretary of State for Health and Social Care, what (a) mechanisms exist and (b) steps he is taking to ensure that integrated care boards are accountable for their commissioning of children’s palliative care.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Breast Cancer

20 Jun 2025 · To ask the Secretary of State for Health and Social Care, if he will take steps to (a) increase awareness of, (b) improve screening for and (c) develop research into lobular breast cancer; and what recent discussions his Department has had with NHS Englan

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Advanced Therapy Medicinal Products

20 Jun 2025 · To ask the Secretary of State for Health and Social Care, if he will designate a Minister in his Department to (a) have responsibility for the field of cell and gene therapies and (b) chair his Department's Advanced Therapies Medicinal Products Coordinati

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Prostate Cancer: Screening

8 Sept 2025 · To ask the Secretary of State for Health and Social Care, what his policy is on (a) routine PSA testing for males in specific age categories and (b) the reimbursement of GP practices by the NHS for providing PSA tests; and whether he has made an assessmen

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Prostate Cancer: Screening

8 Sept 2025 · To ask the Secretary of State for Health and Social Care, how many and what proportion of PSA tests have (a) accurately diagnosed, and (b) given false (i) negative and (ii) positive diagnoses for prostate cancer in the most recent year for which figures a

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Prostate Cancer: Medical Treatments

27 Oct 2025 · To ask the Secretary of State for Health and Social Care, with reference to the National Cancer Audit Collaborating Centre's report entitled National Prostate Cancer Audit State of the Nation Report 2025, published in October 2025, what assessment his Dep

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Psilocybin: Clinical Trials

28 Oct 2025 · To ask the Secretary of State for Health and Social Care, whether he has received evidence on the potential clinical use of psilocybin under controlled conditions to treat serious psychiatric illness; whether his Department has made an assessment of the p

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Omaveloxolone

3 Nov 2025 · To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the reasons for the difference in availability of Omaveloxolone (Skyclarys) as a treatment for Friedrich's ataxia in (a) Scotland and (b) England a